Hemogenyx Pharmaceuticals Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Vladislav Sandler
Chief Executive Officer (CEO)
UK£397.0k
Compensación total
| Porcentaje del salario del CEO | 98.0% |
| Permanencia del CEO | 10.9yrs |
| Participación del CEO | 3.0% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 7.1yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Hemogenyx Pharmaceuticals (LON:HEMO) In A Good Position To Deliver On Growth Plans?
Aug 21
Will Hemogenyx Pharmaceuticals (LON:HEMO) Spend Its Cash Wisely?
May 04We Think Hemogenyx Pharmaceuticals (LON:HEMO) Needs To Drive Business Growth Carefully
Jan 06Hemogenyx Pharmaceuticals (LON:HEMO) Has Debt But No Earnings; Should You Worry?
Oct 09Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -UK£5m |
| Mar 31 2024 | n/a | n/a | -UK£6m |
| Dec 31 2023 | UK£397k | UK£389k | -UK£7m |
| Sep 30 2023 | n/a | n/a | -UK£7m |
| Jun 30 2023 | n/a | n/a | -UK£7m |
| Mar 31 2023 | n/a | n/a | -UK£6m |
| Dec 31 2022 | UK£282k | UK£276k | -UK£4m |
| Sep 30 2022 | n/a | n/a | -UK£3m |
| Jun 30 2022 | n/a | n/a | -UK£3m |
| Mar 31 2022 | n/a | n/a | -UK£4m |
| Dec 31 2021 | UK£213k | UK£206k | -UK£5m |
| Sep 30 2021 | n/a | n/a | -UK£5m |
| Jun 30 2021 | n/a | n/a | -UK£5m |
| Mar 31 2021 | n/a | n/a | -UK£3m |
| Dec 31 2020 | UK£205k | UK£200k | -UK£2m |
| Sep 30 2020 | n/a | n/a | -UK£2m |
| Jun 30 2020 | n/a | n/a | -UK£2m |
| Mar 31 2020 | n/a | n/a | -UK£2m |
| Dec 31 2019 | UK£149k | UK£145k | -UK£1m |
| Sep 30 2019 | n/a | n/a | -UK£2m |
| Jun 30 2019 | n/a | n/a | -UK£2m |
| Mar 31 2019 | n/a | n/a | -UK£2m |
| Dec 31 2018 | UK£98k | UK£94k | -UK£2m |
| Sep 30 2018 | n/a | n/a | -UK£2m |
| Jun 30 2018 | n/a | n/a | -UK£3m |
| Mar 31 2018 | n/a | n/a | -UK£3m |
| Dec 31 2017 | UK£79k | UK£79k | -UK£2m |
Compensación vs. Mercado: La compensación total de Vladislav($USD503.23K) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD353.74K).
Compensación vs. Ingresos: La compensación de Vladislav ha aumentado mientras la empresa no es rentable.
CEO
Vladislav Sandler (59 yo)
10.9yrs
Permanencia
UK£397,000
Compensación
Dr. Vladislav Sandler, Ph D., is a Co-Founder of Hemogenyx Pharmaceuticals Plc. and serves as its Chief Executive Officer since December 2013 and serves as its Director.Dr. Sandler also serves as Chief Ex...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder | 7.1yrs | UK£397.00k | 2.96% £ 444.5k | |
| Independent Co-Founder & Non-Executive Director | 7.1yrs | UK£60.00k | 5.36% £ 803.5k | |
| Clinical Advisor & Medical Director | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | 6.7yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 9.3yrs | UK£50.00k | 0.40% £ 59.9k | |
| Independent Chairman & Chairman of Advisory Board | 7.2yrs | UK£15.00k | sin datos |
7.1yrs
Permanencia media
74yo
Promedio de edad
Junta con experiencia: La junta directiva de HEMO se considera experimentada (7.1 años de antigüedad promedio).